Business
Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France
The French National Agency for the Safety of Medicines and Health Products (ANSM) Selects Tilray for First Medical Cannabis Experiment with Patients in
About this update from Tilray Brands, Inc.
[{"type":"text","content":"\nThe French National Agency for the Safety of Medicines and Health Products (ANSM) Selects Tilray for First Medical Cannabis Experiment with Patients in France\n\n NANAIMO, British Columbia & PARIS--(BUSINESS WIRE)--\nTilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France. Tilray will supply GMP-produced medical cannabis products to serve patients in need for the duration of the French experiment (18-24 months), due to begin in the first quarter of 2021.\n\nTilray products will be administered to qualifying patients in the French experiment, for whom existing treatments do not provide sufficient relief from their symptoms, and for therapeutic indications including:\n\n\nNeuropathic pain that is refractory to therapies currently available (drug or non-drug treatments);\n\n\nCertain forms of epilepsy that are drug-resistant;\n\n\nIn certain persistent symptoms in oncology, related to cancer or anti-cancer treatment;\n\n\nIn palliative care situations;\n\n\nIn the painful spasticity of multiple sclerosis or other pathologies of the central nervous system.\n\n\nTilray has received the necessary regulatory approvals to participate in the ANSM experimentation in France and will export medical cannabis products from its GMP-certified facility in Cantanhede, Portugal.\n\nBrendan Kennedy, Tilray’s Chief Executive Officer, said, “Today's announcement marks another milestone for Tilray as we expand operations in Europe. We are proud to be able to offer access to a variety of high-quality, pharmaceutical-grade medical cannabis products to the ANSM while supporting patients in need in France.”\n\nSascha Mielcarek, Tilray’s General Manager for Europe, said, “We are pleased to be chosen by the ANSM and fully appreciate the stakes of this experiment for French patients, and we are determined to contribute to its success actively. Tilray is once again establishing itself as a key player with solid expertise in the service of patient well-being.”\n\nTilray's E.U. Campus in Portugal is a multi-faceted production facility that includes research and quality control ...